Market Place
Sourcing Support
Genentech axes Nykode cancer vaccine deal
09 Nov 2024 //
FIERCE BIOTECH
Nykode Announces Expansion of Clinical Collaboration with Roche
01 Jun 2023 //
GLOBENEWSWIRE
Nykode Therapeutics to Present at Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Nykode announces positive final results from its Phase 2 trial of VB10.16
18 Apr 2023 //
GLOBENEWSWIRE
Nykode Therapeutics to announce financial results for the fourth quarter 2022
22 Feb 2023 //
GLOBENEWSWIRE
Nykode Announces Collaboration with The GOG Foundation to Conduct VB-C-04 Trial
10 Feb 2023 //
GLOBENEWSWIRE
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Nykode Therapeutics and Richter-Helm BioLogics Enter Manufacturing Partnership
03 Jan 2023 //
CONTRACT PHARMA
Nykode to Present at the 41st Annual J.P. Morgan Healthcare Conference
23 Dec 2022 //
GLOBENEWSWIRE
Nykode announces expanded clinical devP plan for its lead cancer vaccine VB10.16
20 Dec 2022 //
GLOBENEWSWIRE
Nykode and Richter-Helm BioLogics Announce Partnership
19 Dec 2022 //
GLOBENEWSWIRE
Nykode Announces Clinical Collaboration with MSD to Evaluate VB10.16
06 Dec 2022 //
GLOBENEWSWIRE
Nykode Therapeutics to announce financial results for the third quarter 2022
16 Nov 2022 //
GLOBENEWSWIRE
Nykode Therapeutics to present at two upcoming investor conferences in November
07 Nov 2022 //
GLOBENEWSWIRE
Nykode presents additional efficacy analysis in Phase 2 study of VB10.16
07 Nov 2022 //
GLOBENEWSWIRE
Nykode to Present on Immunogenicity Results from Ph1/2a Study of VB10.NEO
26 Oct 2022 //
GLOBENEWSWIRE
Nykode hits early-stage goals for pan-variant COVID shot
27 Sep 2022 //
FIERCEBIOTECH
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Labe
26 Sep 2022 //
GLOBENEWSWIRE
Nykode Therapeutics to present at H.C. Wainwright Global Investment Conference
09 Sep 2022 //
GLOBENEWSWIRE
Nykode Therapeutics to announce financial results for the first half of 2022
22 Aug 2022 //
GLOBENEWSWIRE
Nykode Therapeutics Announces Positive Interim Results in PII Trial
21 Jun 2022 //
BUSINESSWIRE
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
16 Jun 2022 //
GLOBENEWSWIRE
Nykode Therapeutics to Present at Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Investors flip-flop on Nykode`s cancer vaccine data drop
09 May 2022 //
FIERCEBIOTECH
Nykode announces positive interim results from its PII trial with VB10.16
09 May 2022 //
GLOBENEWSWIRE
Nykode Tx to Present at 2022 AACR
08 Mar 2022 //
GLOBENEWSWIRE
Nykode concludes subject enrolment in Phase II cervical cancer vaccine trial
14 Feb 2022 //
CLINICALTRIALSARENA
Nykode Tx completes patient enrollment in Phase 2 of VB10.16 + atezolizumab
10 Feb 2022 //
GLOBENEWSWIRE
Nykode doses first participant in Phase I/II Covid-19 vaccine trial
29 Dec 2021 //
CLINICALTRIALSARENA
Nykode Begins Dosing of T cell focused next-gen SARS-CoV-2 vaccine candidate
27 Dec 2021 //
GLOBENEWSWIRE
Vaccibody Has a New Name and a Fresh Partnership with Regeneron
24 Nov 2021 //
BIOSPACE
